The pharmacological development of IPW-5371 fumarate as a radiation medical countermeasure for the treatment of delayed radiation lung injury under the FDA animal rule
Award Notice Posted
- Solicitation number
- NIAID-BAA-75N93021R00019
- Agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Awarded
- to Innovation Pathways, LLC
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- 75N93023C00014 Federal contract award
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Place of performance
- Palo Alto, California 94301, United States
Notice details come from SAM.gov. Updated .
About this opportunity
Innovation Pathways LLC was awarded a single contract valued at $4,499,688 by the National Institute of Allergy and Infectious Diseases to pharmacologically develop IPW-5371 fumarate as a radiation medical countermeasure for the treatment of delayed radiation lung injury according to FDA animal rule guidelines by July 1, 2023. The contract will support the awardee's work to gain FDA approval for their countermeasure under the animal efficacy rule for treating delayed radiation lung injury.
Notice text
Awarded contract 75N93023C00014 to INNOVATION PATHWAYS LLC for 4499688.00 on 2023-07-01.
Notice history
10 of 12 notices listed here. See the rest on GovTribe.
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity